CSI Market
Sign In | Register

Catalyst Pharmaceuticals Inc (CPRX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CPRX quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Catalyst Pharmaceuticals Inc manages cash inflows and outflows over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income214.33
Depreciation & amortization0.38
Amortization of Other Assets37.50
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-18.09
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation24.78
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Non Cash Change In Right Of Use Asset0.30
Increase Decrease In Operating Lease Liability-0.40
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-61.00
Increase (Decrease) in Accounts Payable-5.39
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities24.16
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-7.03
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.86
Discontinued operations0.00
Net Cash flow from Operating Activities208.67
Investing Activities
Capital Expenditures-0.06
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Proceeds From Certificates Of Deposit-
Payment In Connection With License Agreement-
Payment In Connection With Asset Acquisition-
Payments To Acquire Equity Securities Fv Ni-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Proceeds from (Payments for) in Interest-bearing Deposits in Banks0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.06
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-10.63
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.77
Proceeds From Issuance Of Common Stock And Warrants Net-
Payment Of Liabilities Arising From Asset Acquisition-4.59
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-16.99
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow208.61
Total Cash Flow191.62
4 historic quarters locked

Sign in to unlock the full Catalyst Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Catalyst Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 25, 2026
  • Source: cprx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-071525

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License